Voyager Therapeutics Files 8-K
Ticker: VYGR · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1640266
Sentiment: neutral
Topics: 8-K, financial-statements, regulation-fd
TL;DR
Voyager Therapeutics filed a routine 8-K on Sept 2, 2025, with financial docs.
AI Summary
Voyager Therapeutics, Inc. filed an 8-K on September 2, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial details or material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing serves as a standard corporate disclosure, indicating that Voyager Therapeutics, Inc. has submitted required financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no new material information or events disclosed.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- September 2, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 75 Hayden Avenue Lexington (address) — Principal Executive Offices
- 02421 (zip_code) — Zip Code for Principal Executive Offices
- 857-259-5340 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Voyager Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to submit Financial Statements and Exhibits as of September 2, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 2, 2025.
In which state is Voyager Therapeutics, Inc. incorporated?
Voyager Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Voyager Therapeutics, Inc.?
The principal executive office address is 75 Hayden Avenue, Lexington, Massachusetts, 02421.
What is the telephone number provided for Voyager Therapeutics, Inc.?
The telephone number provided for Voyager Therapeutics, Inc. is (857) 259-5340.
Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2025-09-02 07:00:53
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select M
Filing Documents
- tm2524800d1_8k.htm (8-K) — 28KB
- tm2524800d1_ex99-1.htm (EX-99.1) — 19KB
- tm2524800d1_ex99-1img001.jpg (GRAPHIC) — 194KB
- tm2524800d1_ex99-1img002.jpg (GRAPHIC) — 389KB
- tm2524800d1_ex99-1img003.jpg (GRAPHIC) — 180KB
- tm2524800d1_ex99-1img004.jpg (GRAPHIC) — 185KB
- tm2524800d1_ex99-1img005.jpg (GRAPHIC) — 217KB
- tm2524800d1_ex99-1img006.jpg (GRAPHIC) — 197KB
- tm2524800d1_ex99-1img007.jpg (GRAPHIC) — 148KB
- tm2524800d1_ex99-1img008.jpg (GRAPHIC) — 143KB
- tm2524800d1_ex99-1img009.jpg (GRAPHIC) — 134KB
- tm2524800d1_ex99-1img010.jpg (GRAPHIC) — 185KB
- tm2524800d1_ex99-1img011.jpg (GRAPHIC) — 220KB
- tm2524800d1_ex99-1img012.jpg (GRAPHIC) — 198KB
- 0001104659-25-085977.txt ( ) — 3509KB
- vygr-20250902.xsd (EX-101.SCH) — 3KB
- vygr-20250902_lab.xml (EX-101.LAB) — 33KB
- vygr-20250902_pre.xml (EX-101.PRE) — 22KB
- tm2524800d1_8k_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Voyager Therapeutics, Inc. (the "Company"), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the "Presentation") at Citi's 2025 Biopharma Back to School Conference on September 2, 2025 at 4:00 p.m. ET. A copy of the Presentation is attached as Exhibit 99.1 to this Current Report onForm8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Item 7.01 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing. By providing the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, the Company is not making an admission as to the materiality of any information herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of more complete information included in the Company's filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Voyager Therapeutics, Inc. Presentation September 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 2, 2025 VOYAGER THERAPEUTICS, INC. By: /s/ Nathan Jorgensen, Ph.D. Nathan Jorgensen, Ph.D. Chief Financial Officer (Principal Financial and Accounting Officer)